Watch the webinar

Manufacturing lentiviral vectors at scale remains challenging as demand grows and cost pressures increase.

This webinar explains how alternative upstream strategies can improve productivity, reduce contaminants, and lower cost of goods while maintaining the quality required for advanced therapy production.

Thomas Robert explores how fixed-bed bioreactor design and perfusion-enabled processing support higher cell densities, improved viral titers, and simplified scale-up compared with conventional stirred-tank approaches. Drawing on process data and technoeconomic modeling from CAR-T manufacturing scenarios, the article demonstrates how optimized upstream workflows can improve downstream recovery and significantly reduce production costs.

Learn more about:

• How cell-immobilized bioreactor systems enable higher viral titers and 3–20× lower host cell protein contamination in clarified harvests
• Why perfusion-enabled upstream processing can increase downstream recovery by 2–3× while simplifying scale-up
• Technoeconomic modeling showing 25–65% reductions in cost of goods per dose and fewer production batches in CAR-T manufacturing scenarios